Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
Condition: HER2-positive Breast Cancer Intervention: Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor: Shandong University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Study | Taxotere